Roham Zamanian

James and Yvonne Wood Professor of Pulmonary Vascular Medicine

Bio

Dr. Roham Zamanian specializes in the treatment of pulmonary hypertension, right heart failure, and pulmonary embolism. He has more than 2 decades of sub-specialty experience in pulmonary vascular diseases. Dr. Zamanian is considered one of the leading international experts in clinical trials and drug development for pulmonary hypertension.

Clinical Focus

Pulmonary Hypertension
pulmonary vascular diseases
pulmonary embolism
right heart failure
Pulmonology (Lung) and Critical Care
Pulmonary Disease

Academic Appointments

Professor - University Medical Line, Medicine - Pulmonary, Allergy & Critical Care Medicine
Member, Cardiovascular Institute
Member, Wu Tsai Human Performance Alliance

Administrative Appointments

Associate Director, Vera Moulton Wall Center for Pulmonary Vascular Disease (2024 - Present)
Director, Adult Pulmonary Hypertension Service, Vera Moulton Wall Center for Pulmonary Vascular Disease (2007 - Present)
Clinical Director, VMWC Pulmonary Hypertension Database, Vera Moulton Wall Center for Pulmonary Vascular Disease (2006 - Present)

Honors & Awards

Howard Huges Summer Fellowship, Harvard School of Medicine (1992 & 1993)
Ralph Waldo Gerard Award for Outstanding Researcher, University of California, Irvine School of Biological Sciences (1994)
Excellence in Research Award, University of California, Irvine School of Biological Sciences (1995)
Case Presentation Award, ACCP - Chest 2000 (2000)
Resident Research Presentation Award, Univ of Calif, Irvine Medical Center - Dept of Medicine (2001)
Fellow of the Year, Univ of Califronia, Irvine Medical Center (2002-2003)
Young Investigator Career Development Award, Entelligence Actelion Young Investigators Program (2006-2007)
Faculty Teaching Award, Dept of Medicine, Stanford (2007)
Fellow of the American College of Chest Physicians, American College of Chest Physicians (2008)

Boards, Advisory Committees, Professional Organizations

Scientific Advisory Board, PHaware (2016 - Present)

Professional Education

Medical Education: University of California at Irvine School of Medicine (1999) CA
Fellowship: Stanford University School of Medicine (2005) CA
Board Certification: American Board of Internal Medicine, Pulmonary Disease (2024)
Fellowship: Stanford University Pulmonary and Critical Care Fellowship (2006) CA
Fellowship: University of Irvine Medical Center (2003) CA
Residency: University of Irvine Medical Center (2002) CA
Internship: University of Irvine Medical Center (2000) CA
Super-Fellowship, Stanford University, Pulmonary Vascular Disease (2006)
Fellowship, Stanford University, Pulmonary & Critical Care (2005)
Fellowship, UCI Medical Center, Pulmonary & Critical Care (2003)
Residency, UCI Medical Center, Internal Medicine (2002)
MD, University of California, Irvine, Medicine (1999)
BS, University of California, Irvine, Biological Sciences (1994)

Community and International Work

Blue Lips Foundation

Topic

Partnering Organization(s)

Populations Served

Location

US

Ongoing Project

true

Opportunities for Student Involvement

false
PHaware

Topic

Partnering Organization(s)

Populations Served

Pulmonary Hypertension Patients

Location

International

Ongoing Project

true

Opportunities for Student Involvement

false
Member PHA Scientific Leadership Council

Topic

Partnering Organization(s)

Pulmonary Hypertension Association

Populations Served

Location

International

Ongoing Project

false

Opportunities for Student Involvement

false

Patents

Edda Spiekerkoetter, Marlene Rabinovitch, Roham Zamanian. "United StatesFK506 for treatment of PAH", Leland Stanford Junior University

Contact

Academic roham.zamanian@stanford.edu

Clinical (Primary)

This is the primary clinic for this clinical provider. For additional clinical locations and information, please visit the link(s) listed below in the 'Additional Clinical Info' section.

Pulmonary and Critical Care 300 Pasteur Dr A251 MC 5221 Stanford CA 94305 Tel: (650) 723-6381 Fax: (650) 725-5489

Additional Clinical Info

Stanford Health Care

Current Research and Scholarly Interests

1. Development and evaluation of prognostic and diagnostic integral biomarkers in PAH.

2. Prevalence and Treatment of Insulin Resistance in PAH.

3. Role of inflammation and proteomic signature in PAH

4. Development of novel therapeutics (bench to bedside) including FK506 & Elastase Inhibition in PAH.

5. Assessment of Vasoreactivity (gain and loss) in pulmonary arterial hypertension

6. Assessment of microvascular function in PAH.

Clinical Trials

OPsumit USers Registry Not Recruiting
More
Prospective observational drug registry developed to characterize the safety profile (including primarily potential serious hepatic risks) and to describe clinical characteristics and outcomes of patients newly treated with Opsumit in the post-marketing setting.

Stanford is currently not accepting patients for this trial. For more information, please contact Spectrum Child Health, 650-724-1175.
Lead Sponsor
Stanford Investigators
- Roham Zamanian
View full details
U.S. CTEPH Registry Not Recruiting
More
The U.S. CTEPH Registry is a multicenter, observational, U.S.-based study of the clinical course and treatment of patients diagnosed with chronic thromboembolic pulmonary hypertension (CTEPH), WHO Group IV Classification for Pulmonary Hypertension. The mission of the Registry will be to promote a greater understanding of the prevalence, pathophysiology, evaluation, and treatment of patients with CTEPH through shared information, education, and collaborative investigation among pulmonary hypertension (PH) centers of excellence throughout the U.S.

Stanford is currently not accepting patients for this trial. For more information, please contact Spectrum Child Health, 650-724-1175.
Lead Sponsor
Stanford Investigators
- Roham Zamanian
View full details
DynAMITE Not Recruiting
More
* Evaluate for accuracy and reproducibility of data collected via the participant-operated Walk.Talk.Track. (WTT) app combined with Apple Watch during in-clinic, technician proctored 6MWT's. * Determine whether the WTT app on the Apple Watch can accurately collect information on distance traveled and heart rate (HR) during in-clinic 6MWT run by American Thoracic Society (ATS) guidelines * Determine whether participants can operate the WTT app and Apple Watch effectively to gather accurate data in a monitored and home-based setting * Prospectively monitor for changes in WTT app recorded 6MWT results following initiation of therapy in a treatment naïve cohort of PAH participants * Evaluate whether changes from baseline in 6 minute walk distance (6MWD) and heart rate recovery at one minute (HRR1) as well as other variables that have been associated with disease severity in PAH and left-sided heart disease (resting HR, heart rate variability \[HRV\], chronotropic index \[CI\]) can be identified before the 12-week follow up when comparing the treatment arm and the control arm * Evaluate whether changes from baseline in the HRR1, resting HR, HRV and/or CI are more evident in treatment responders when compared to treatment non-responders.

Stanford is currently not accepting patients for this trial. For more information, please contact Alejandra Elizabeth Lopez, 650-725-4000.

Lead Sponsor
- Stanford University
Stanford Investigators
- Vinicio de Jesus Perez MD
- Roham Zamanian
View full details
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH) Not Recruiting
More
Systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) is a serious, life-threatening manifestation of systemic sclerosis (SSc), an autoimmune disease of the connective tissue characterized by scarring (fibrosis) and atrophy of the skin, joints and tendons, skeletal muscles, and internal organs, and immunological disturbances. One-year survival for patients with SSc-PAH ranges from 50-81%. There is currently no cure for SSc-PAH and treatment is limited to vasodilator therapy used in all forms of PAH. In recent studies, immunotherapy was shown to be effective in treating SSc-interstitial lung disease, another serious, life-threatening manifestation of SSc. In addition, there are compelling pre-clinical data and anecdotal clinical reports that suggest modulation of the immune system may be an effective strategy for treating SSc-PAH. To test this approach, this trial will determine if rituximab, an immunotherapy, has a marked beneficial effect on clinical disease progression, with minimal toxicity, in patients with SSc-PAH when compared to placebo.

Stanford is currently not accepting patients for this trial. For more information, please contact Val Scott, 650-725-8082.
Lead Sponsor
Stanford Investigators
View full details
Pulmonary Hypertension Association Registry Recruiting
More
The PHA Registry (PHAR) is a national study about people who have pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). PHAR collects information from people with PAH and CTEPH who are cared for in participating PHA-accredited Pulmonary Hypertension Care Centers throughout the U.S. PHAR will determine how people with PAH and CTEPH are evaluated, tested, and treated, and will observe how well these participants do. The goal is to see if people with PH are treated according to recommended guidelines, and to see if there are certain factors that can lead to better or worse outcomes. PHAR will include information about people with PAH and CTEPH in the U.S. who are seen at participating PHA-accredited PH Care Centers. PHAR contains data about patient care and outcomes. Specifically, data in the PHAR includes information on diagnosis; clinical status; socioeconomic status; diagnosis test results; body size; treatment information; interest in participating in clinical trials; family health and social history; and information about smoking, alcohol, or drug use. Participants are followed over time, and provide updates such as changes in therapy, how often participants need to go to the hospital, and survival. Such information may help healthcare providers provide better care.
Lead Sponsor
Stanford Investigators
- Roham Zamanian
View full details

2025-26 Courses

Independent Studies
- Directed Reading in Medicine
  MED 299 (Aut, Win, Spr, Sum)
- Early Clinical Experience in Medicine
  MED 280 (Aut, Win, Spr, Sum)
- Graduate Research
  MED 399 (Aut, Win, Spr, Sum)
- Medical Scholars Research
  MED 370 (Aut, Win, Spr, Sum)
- Undergraduate Research
  MED 199 (Aut, Win, Spr, Sum)

Stanford Advisees

Postdoctoral Faculty Sponsor
Or Bruck, Perry Rabin

Find a doctor

Clinics & Services

Research Resources

Professional Training

Education Resources

Roham Zamanian

James and Yvonne Wood Professor of Pulmonary Vascular Medicine

Topic

Partnering Organization(s)

Populations Served

Location

Ongoing Project

Opportunities for Student Involvement

Topic

Partnering Organization(s)

Populations Served

Location

Ongoing Project

Opportunities for Student Involvement

Topic

Partnering Organization(s)

Populations Served

Location

Ongoing Project

Opportunities for Student Involvement

Stanford Investigators

Stanford Investigators

Lead Sponsor

Stanford Investigators

Stanford Investigators

Stanford Investigators

2025-26 Courses

Stanford Advisees